

Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)

NCT05814952

Status	RECRUITING
Phase	Not Applicable
Sponsor	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Enrollment	12 participants

Key Eligibility Criteria

Inclusion (3)

- Willing to sign the informed consent, and willing to attend follow-up visits.
- Male individual at least 6 years of age with a diagnosis of XLRS and documented mutations in the RS1 gene.
- The study eye must have a best-corrected E-ETDRS visual acuity letter score of less than or equal to 63.

Exclusion (4)

- Any eye with disease that would interfere with the fundus examinations.
- The study eye is receiving topical carbonic anhydrase inhibitor, or has received topical carbonic anhydrase inhibitors in the past three months.
- The study eye has undergone intraocular surgery within six months prior to enrollment.
- Participant has uncontrolled hypertension or diabetes.

Locations (1 total)

Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China